Search

Your search keyword '"Brunotte, F."' showing total 437 results
Start Over Author "Brunotte, F."
437 results on '"Brunotte, F."'

11. Imagerie moléculaire

Author

Collin, B., primary, Cochet, A., additional, Humbert, O., additional, Vrigneaud, J.-M., additional, Oudot, A., additional, Lalande, A., additional, Walker, P. M., additional, Denat, F., additional, Brunotte, F., additional, and Fumoleau, P., additional

Published
2014
Full Text
View/download PDF

20. A new family of tacn derivatives for 64Cu and 68Ga chelation

Author

Denat, F., primary, Poty, S., additional, Brunotte, F., additional, Simecek, J., additional, Notni, J., additional, Wester, HJ., additional, Raguin, O., additional, Boschetti, F., additional, Goncalves, V., additional, Goze, C., additional, Désogère, P., additional, Bernhard, C., additional, Moreau, M., additional, and Collin, B., additional

Published
2019
Full Text
View/download PDF

26. BODIPY: a highly versatile platform for the design of MonoMolecular Multimodal Imaging Probes

Author

Goze, Christine, Ipuy, M., Maindron, N., Lhenry, D., Bernhard, Claire, Moreau, Mathieu, Provent, P., Oudot, A., Collin, B., Vrigneaud, J., Brunotte, F., Denat, Franck, Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] ( ICMUB ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), OncoDesign, Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] (ICMUB), Université de Bourgogne (UB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Oncodesign [Dijon], Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), and UNICANCER

Subjects
[SDV.IB]Life Sciences [q-bio]/Bioengineering, [ SDV.IB ] Life Sciences [q-bio]/Bioengineering, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016
Full Text
View/download PDF

29. Theranostic gadolinium-based nanoparticles AGuIX®: in vivo imaging and safety evaluation

Author

Sancey, Lucie, Kotb, S., Piraquive Agudelo, J., Bouziotis, P., Brunotte, F., Denat, F., Boschetti, F., Mouriot, S., Taborik, F., Canet-Soulas, Emmanuelle, Contamin, H., Lux, F., Tillement, O., Institut Lumière Matière [Villeurbanne] (ILM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), National Center for Scientific Research 'Demokritos' (NCSR), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] (ICMUB), Université de Bourgogne (UB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), CheMatech - Macrocycle Design Technologies, Cynbiose, CYNBIOSE, Institut Lumière Matière [Villeurbanne] ( ILM ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Cardiovasculaire, métabolisme, diabétologie et nutrition ( CarMeN ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hospices Civils de Lyon ( HCL ) -Institut National des Sciences Appliquées de Lyon ( INSA Lyon ), Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université de Lyon-Institut National des Sciences Appliquées ( INSA ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Institut National de la Recherche Agronomique ( INRA ), NCSR Demokritos, Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] ( ICMUB ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), and Rayet, Béatrice

Subjects
[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.CAN]Life Sciences [q-bio]/Cancer, [ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/Imaging, [ SDV.CAN ] Life Sciences [q-bio]/Cancer
Abstract

International audience; IntroductionA new efficient type of gadolinium (Gd)-based theranostic agent (AGuIX®) has recently been developed for MRI-guided radiotherapy.1 These nanoparticles consist of a polysiloxane network surrounded by Gd chelates. Nanoparticles, which contain high-Z contrast agents such as Gd-based nanoparticles, increase the sensitivity of the tumor to radiation. Owing to their small size (3 +/- 0.1 nm), AGuIX® typically exhibit biodistributions that are almost ideal for diagnostic and therapeutic purposes.2 Multi-imaging properties and safety evaluation of the Gd-based nanoparticles have been investigated before their clinical transfer. MethodsGd-based nanoparticles have been administrated to rats-bearing tumor and non-human primates for MRI and PET investigations. In parallel, regulatory investigations have been performed on both rodents and non-human primates.

Published
2015

31. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET

Author

Moreau, M., primary, Poty, S., additional, Vrigneaud, J.-M., additional, Walker, P., additional, Guillemin, M., additional, Raguin, O., additional, Oudot, A., additional, Bernhard, C., additional, Goze, C., additional, Boschetti, F., additional, Collin, B., additional, Brunotte, F., additional, and Denat, F., additional

Published
2017
Full Text
View/download PDF

32. Radiolabeled F(ab′)2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models.

Author

Bellaye, P.-S., Moreau, M., Raguin, O., Oudot, A., Bernhard, C., Vrigneaud, J.-M., Dumont, L., Vandroux, D., Denat, F., Cochet, A., Brunotte, F., and Collin, B.

Abstract

Purpose: This study aimed to investigate theranostic strategies in colorectal and skin cancer based on fragments of cetuximab, an anti-EGFR mAb, labeled with radionuclide with imaging and therapeutic properties, 111In and 177Lu, respectively.Methods: We designed F(ab′)2-fragments of cetuximab radiolabeled with 111In and 177Lu. 111In-F(ab′)2-cetuximab tumor targeting and biodistribution were evaluated by SPECT in BalbC nude mice bearing primary colorectal tumors. The efficacy of 111In-F(ab′)2-cetuximab to assess therapy efficacy was performed on BalbC nude mice bearing colorectal tumors receiving 17-DMAG, an HSP90 inhibitor. Therapeutic efficacy of the radioimmunotherapy based on 177Lu-F(ab′)2-cetuximab was evaluated in SWISS nude mice bearing A431 tumors.Results: Radiolabeling procedure did not change F(ab′)2-cetuximab and cetuximab immunoreactivity nor affinity for HER1 in vitro. 111In-DOTAGA-F(ab′)2-cetuximab exhibited a peak tumor uptake at 24 h post-injection and showed a high tumor specificity determined by a significant decrease in tumor uptake after the addition of an excess of unlabeled-DOTAGA-F(ab′)2-cetuximab. SPECT imaging of 111In-DOTAGA-F(ab′)2-cetuximab allowed an accurate evaluation of tumor growth and successfully predicted the decrease in tumor growth induced by 17-DMAG. Finally, 177Lu-DOTAGA-F(ab′)2-cetuximab radioimmunotherapy showed a significant reduction of tumor growth at 4 and 8 MBq doses.Conclusions: 111In-DOTAGA-F(ab′)2-cetuximab is a reliable and stable tool for specific in vivo tumor targeting and is suitable for therapy efficacy assessment. 177Lu-DOTAGA-F(ab′)2-cetuximab is an interesting theranostic tool allowing therapy and imaging. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

33. Etude multicentrique de l'impact de la TEP/TDM à la fluorocholine (18F) en cas de récidive occulte de cancer de la prostate

Author

Huchet, V., Rousseau, Chloé, Brunotte, F., Olivier, P., Courbon, H., Foehrenbach, H., Bonichon, F., Garin, E., Vera, Pierre, Mundler, O., Kotzki, Pierre-Olivier, Giammarile, F., Darcourt, J., Girault, S., Baulieu, Jl, Talbot, Jn, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Service de médecine nucléaire [Marseille], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Médecine Nucléaire [Nîmes], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Breton, Céline, Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), and Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2011

34. Minor changes in the macrocyclic ligands but major consequences on the efficiency of gold nanoparticles designed for radiosensitization

Author

Laurent, G., primary, Bernhard, C., additional, Dufort, S., additional, Jiménez Sánchez, G., additional, Bazzi, R., additional, Boschetti, F., additional, Moreau, M., additional, Vu, T. H., additional, Collin, B., additional, Oudot, A., additional, Herath, N., additional, Requardt, H., additional, Laurent, S., additional, Vander Elst, L., additional, Muller, R., additional, Dutreix, M., additional, Meyer, M., additional, Brunotte, F., additional, Perriat, P., additional, Lux, F., additional, Tillement, O., additional, Le Duc, G., additional, Denat, F., additional, and Roux, S., additional

Published
2016
Full Text
View/download PDF

37. Bone metastasis of a breast cancer detected by 3 '-deoxy-3 '-F-18-fluorothymidine PET/CT

Author

Cochet, A., Berriolo-Riedinger, A., Girault, A., Rousseau, S., Brunotte, F., Couturier, Olivier-François, Service de RMN Spectroscopie, Médecine Nucléaire (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), and Univ Angers, Okina

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2009

38. [Role of visual analysis of first-pass contrast-enhanced MRI in reperfused myocardial infarction]

Author

Cochet A, Cottin Y, Comte A, Zeller M, Alain Lalande, Touzery C, Pm, Walker, Voguet S, L'Huillier I, Je, Wolf, Brunotte F, Laboratoire Electronique, Informatique et Image ( Le2i ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Observatoire RICO (ObseRvatoire des Infarctus de Côte d’Or) [Dijon], Observatoire des Infarctus de Côte-d'Or (RICO) [Dijon], Service de cardiologie, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), CHU Dijon, Service de Cardiologie [CHU de Dijon], Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), and Cochet, Alexandre

Subjects
Gadolinium DTPA, Male, Myocardium, Myocardial Infarction, Contrast Media, Myocardial Reperfusion, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Recovery of Function, Middle Aged, Image Enhancement, Magnetic Resonance Imaging, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, [ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Evaluation Studies as Topic, Humans, Female, ComputingMilieux_MISCELLANEOUS, Angioplasty, Balloon, Aged, Retrospective Studies
Abstract

The aim of this work is to evaluate the relationship between improvement of regional myocardial function and visual analysis of contrast-enhanced (CE) MRI in patients after acute myocardial infarction. MRI was performed on 19 patients 1 and 11 weeks after a reperfused acute myocardial infarction. Perfusion data (first-pass images [FPI] and delayed CE images) were acquired after an intravenous bolus of gadolinium-DTPA and visually analyzed using a 17 segment model. Each segment was then classified in 3 groups, according to the presence or absence of FPI and CE patterns at baseline study: group 0: normal-appearing segments; group 1: segments with delayed hyper-enhancement but no early hypo-enhancement; group 2: segments with early hypoenhancement. Relative Wall thickening (RWT) was analyzed in each segment and its improvement evaluated in each group. Between first MRI and follow-up study, a significant improvement of RWT occurred in group 1 (mean +/- SD) [from 43.43 +/- 26.59% to 76.71 +/- 47.38%; p = 0.001] but not in group 2 (from 32.73 +/- 25.58% to 39.57 +/- 30.57%; p = NS). In group 0, RWT despite normal value at baseline study exhibited a significant improvement at follow-up (from 65.23 +/- 46.52% to 79.73 +/- 48.46%; p = 0.0015). In conclusion, the combined analysis of early and delayed perfusion abnormalities in MRI in the week following myocardial infarction can predict myocardial viability and allows in the future an evaluation of the efficacy of perfusion therapy.

Published
2006

45. [Spontaneous hyperdense intracranial vessels seen on CT scan in polycythemia cases]

Author

DOURAIED BEN SALEM, Gv, Osseby, Rezaizadeh-Bourdariat K, Pastural G, Martin D, Brunotte F, Moreau T, Giroud M, and Binnert D

Subjects
Adult, Male, Polycythemia, Cerebral Arteries, Cranial Sinuses, Middle Aged, Cerebral Veins, Diagnosis, Differential, Hemoglobins, Hematocrit, Linear Models, Circle of Willis, Humans, Female, Child, Tomography, X-Ray Computed, Aged, Retrospective Studies
Abstract

A better understanding of the significance of diffuse hyperdensity affecting the circle of Willis and the dural sinuses on unenhanced CT.We performed a retrospective study of 19 patients with a neurological manifestation and a CT scan without contrast injection. Among these 19 patients, six had been included because of primary or secondary polycythemia. The analysis of cerebral CT scans was made qualitatively by visual inspection and quantitatively.In patients with a hematocrit percentage exceeding 60%, both circle of Willis and dural sinuses were dense on unenhanced CT scans. A linear relation between the hemoglobin level and the contrast of the dural sinuses compared with the grey matter was observed with an excellent correlation (r = 0.934; n0.0001; p = 19).Increased density of cerebral vessels on unenhanced CT is a sign of a high hemoglobin level.

Published
2003

46. [Phosphorus NMR spectroscopy. Its value in the diagnosis of metabolic myopathies. A case of Mac Ardle's disease]

Author

Kaminsky P, Mariarosa AB Melone, Brunotte F, Jm, Escanye, Robin B, Floquet J, Ml, Duc, Robert J, Duc M, Kaminsky, P, Melone, Mariarosa Anna Beatrice, Brunotte, F, Escanye, Jm, Robin, B, Floquet, J, Duc, Ml, Robert, J, and Duc, M.

Subjects
Adult, Magnetic Resonance Spectroscopy, Muscular Diseases, Reference Values, Glycogen Storage Disease Type V, Humans, Female, Phosphorus, Isoelectric Point
Abstract

Phosphorus nuclear magnetic resonance spectroscopy is a non-invasive method used to study muscle bioenergetics in vivo. A new case of Mc Ardle's disease (myophosphorylase deficiency) is reported here. In a context of metabolic myopathy this method can provide a diagnosis of glycogenosis. The spectra obtained at exercise and during recovery determine the degree of enzyme deficiency with satisfactory precision.

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results